Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $85 Per Share Cash Deal
Vertex Pharmaceuticals (VRTX) has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in a cash deal valued at approximately $10 billion. The acquisition is expected to close by the third quarter of 2026 and will be financed through Vertex's existing cash reserves and $4.5 billion in bridge financing from Bank of America and Morgan Stanley.